Latest News
- Psoriasis
Thursday, June 21, 2018
FDA-Approved Label Update: Cosentyx Inhibits Progression of Joint Structural Damage in PsA
The US FDA has approved a label update for Cosentyx® (secukinumab) from Novartis, including data that show the treatment significantly slows the progression of joint structural damage at Week 24 v…
Read the full storyMonday, June 18, 2018
Valeant: FDA Issues Complete Response Letter for Duobrii
Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. has received a Complete Response Letter (CRL) from the US FDA regarding the company's New Drug Application …
Read the full story
Wednesday, June 06, 2018
Luma Therapeutics Launches Novel illuvinate Phototherapy System
Luma Therapeutics has launched illuvinate as an innovative and modern twist on the Goeckerman regimen. By combining a narrowband UVB LED light with patented hydrogels containing coal tar micro-globule…
Read the full story
Tuesday, May 29, 2018
FDA Approves Cimzia for Moderate to Severe Plaque Psoriasis
The FDA has approved extending the label for UCB's Cimzia (certolizumab pegol) to include a new indication in adults with moderate to severe plaque psoriasis. Cimzia is indicated for the treatment…
Read the full storyThursday, May 24, 2018
Psoriatic Arthritis Awareness Project Launches
In recognition of Psoriatic Arthritis Action Month, the National Psoriasis Foundation (NPF), in collaboration with Novartis Pharmaceuticals Corporation, has premiered the Psoriatic Arthritis (PsA) Awa…
Read the full story
Tuesday, May 22, 2018
FDA Approves Lilly's Taltz for Label Update to Treat Psoriasis Involving the Genital Area
The FDA has approved a label update for Taltz (ixekizumab) injection 80 mg/mL to include data in psoriasis involving the genital area. Eli Lilly and Company's Taltz is the first treatment FDA…
Read the full story
Tuesday, May 15, 2018
National Psoriasis Foundation Honors Dr. Jerry Bagel with Excellence in Leadership Award
Jerry Bagel, MD, an internationally recognized expert in the treatment of psoriasis and founder of Windsor Dermatology and Psoriasis Treatment Center of Central New Jersey, will receive the Excellence…
Read the full storyFriday, May 11, 2018
Valeant is Becoming Bausch Health Companies, Inc.
Bausch Health Companies, Inc. will become the new name of Valeant Pharmaceuticals International, Inc., effective in July 2018. Based on the strong brand equity of the company’s businesses a…
Read the full story
Tuesday, May 01, 2018
Encore Dermatology Launches Impoyz Cream 0.025%, a Newly Formulated High-Potency Topical Corticosteroid
Encore Dermatology Inc. launched its new topical product, Impoyz Cream, indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. Impoyz Cream is the onl…
Read the full storyMonday, April 09, 2018
Ortho Dermatologics’ DUOBRII Improves Psoriasis Symptoms As Early As Two Weeks
DUOBRII (halobetasol propionate and tazarotene) (IDP-118) lotion demonstrated significant superiority over vehicle as early as two weeks, according to new research in Journal of the American Academy o…
Read the full storyWednesday, April 04, 2018
GlobalData: Sun Pharma’s Ilumya To Face Strong Competition in the US market
It’s a tough road ahead for Sun Pharma’s newly approved Ilumya, according to a new report from GlobalData, a leading data and analytics company. In March 2018 the US Food and Drug…
Read the full storyFriday, March 30, 2018
Escalier Biosciences Closes Financing, Focuses on Psoriasis
Escalier Biosciences BV, a privately held biopharmaceutical company, this month closed $19 million Series B financing. The round was led by Forbion with existing investors New Science Ventur…
Read the full storyTuesday, March 27, 2018
Skin of Color Society Reports Banner Year
Kudos to the Skin of Color Society (SOCS) for a banner year. At its recent annual business meeting held in conjunction with the 2018 Annual Meeting of the American Academy of Dermatology, SOCS…
Read the full storyThursday, March 22, 2018
FDA Approves Label Update for Cimzia Addressing Low Risk of Fetal Exposure
The FDA has approved a label update that includes pharmacokinetic data showing negligible to low transfer of Cimzia® (certolizumab pegol) through placenta and minimal transfer to …
Read the full story
Wednesday, March 21, 2018
Sun Pharma: FDA Approves Ilumya for Adult Psoriasis
The FDA has approved Ilumya™ (tildrakizumab-asmn) from Sun Pharma for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Il…
Read the full story
